Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Free Cash Flow (2016 - 2025)

Amicus Therapeutics' Free Cash Flow history spans 16 years, with the latest figure at $19.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 556.16% year-over-year to $19.2 million, compared with a TTM value of $33.1 million through Dec 2025, up 188.32%, and an annual FY2025 reading of $33.1 million, up 188.32% over the prior year.
  • Free Cash Flow for Q4 2025 was $19.2 million at Amicus Therapeutics, down from $32.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was $32.8 million in Q3 2025, with the low at -$83.4 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$22.4 million, with a median of -$22.3 million recorded in 2021.
  • Year-over-year, Free Cash Flow crashed 245.59% in 2023 and then surged 556.16% in 2025.
  • Tracing FOLD's Free Cash Flow over 5 years: stood at -$69.8 million in 2021, then dropped by 19.49% to -$83.4 million in 2022, then skyrocketed by 109.94% to $8.3 million in 2023, then plummeted by 150.66% to -$4.2 million in 2024, then surged by 556.16% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Free Cash Flow are $19.2 million (Q4 2025), $32.8 million (Q3 2025), and -$26.5 million (Q2 2025).